

# PATENT MAIL STOP RCE

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re:

Patent Application of

David Berd

:

Appln. No.:

09/776,250

Examiner: Karen A. Canella, Ph.D.

Filed:

February 1, 2001

Attorney Docket No.

: Group Art Unit: 1643

061266-5004-00

For:

LOW DOSE HAPTENIZED TUMOR

CELL AND TUMOR CELL EXTRACT

**IMMUNOTHERAPY** 

#### INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.97 and 1.98 and to the duty of disclosure set forth in 37 C.F.R. § 1.56, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO/SB/08A and PTO/SB/08B submitted herewith. Since the Patent Office has waived the requirement under 37 C.F.R. §1.98(a)(2)(i) for submitting copies of cited U.S. Patents, the U.S. references are not enclosed.

Although the information submitted herewith may be "material" to the Examiner's consideration of the subject application, this submission is not intended to constitute an admission that such information is "prior art" as to the claimed invention.

In accordance with 37 C.F.R. § 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made.

This Supplemental Information Disclosure Statement is being filed before the mailing of a first Office Action after the filing of a Request for Continued Examination. Accordingly, no fee is required. 37 C.F.R. 1.97(b)(4).

#### Respectfully submitted,

ril 19,2007

By:

GAIL H. GRAFFIN

DAVID BERD

Registration No. 51,941 LOUIS W. BEARDELL Registration No. 40,506

MORGAN, LEWIS & BOCKIUS, LLP

1701 Market Street

Philadelphia, PA 19103-2921 Telephone: (215) 963-5000 Direct Dial: (215) 963-5265 Facsimile: (215) 963-5001

E-Mail: ggriffin@morganlewis.com

Attorneys for Applicants

Enclosures Form PTO/SB/08A (1 page)

Form PTO/SB/08B (4 pages) 30 Non-Patent References

PTO/SB/08A (09-06)

Approved for use through 03/31/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE work Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

RAD Situte for form 1449/PTO

Sheet 1

(Use as many sheets as necessary)

Complete if Known				
Application Number	09/776,250			
Filing Date	February 1, 2001			
First Named Inventor	David Berd			
Art Unit	1643			
Examiner Name	Karen A. Canella, Ph.D.			
Attorney Docket Number	061266-5004-00			

			U. S. PATEN	DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Document Number  Number-Kind Code <sup>2 (f known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		<sup>US-</sup> 5,747,269	5/5/1998	Rammensee et al.	
		<sup>US-</sup> 5,487,982	1/30/1996	Salter	
		<sup>US-</sup> 5,827,516	10/27/1998	Urban et al.	
		<sup>US-</sup> 6,458,369	10/1/2002	Berd	
		US-			
	ļ	US-			
		US-			
		US-			
	ļ-	US-			
		US-			
		US-			•
		US-			
		US-			

	FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	<b>-6</b>				
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear					
						igwdap				
	ļ									
	ļ					Щ				
	<u> </u>		<u> </u>							

Examiner	Date	
Signature	Considered	
•		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include of reference copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. The Third T Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND** TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERC

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PADEMA	for form 1449/PTO			Complete if Known			
Gubsiliale	10/10/11/1443//10			Application Number	09/776,250		
INFO	RMATION	DIS	CLOSURE	Filing Date	February 1, 2001		
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	David Berd		
	(11	-4		Art Unit	1643		
(Use as many sheets as necessary)			ecessary)	Examiner Name	Karen A. Canella, Ph.D.		
Sheet 2	2	of	5	Attorney Docket Number	061266-5004-00		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		D. Berd et al., U.S. Patent Application No. 08/203,004, filed February 28,1994.	
		D. Berd et al., U.S. Patent Application No.08/479,016, filed June 7, 1995.	ŀ
		David Berd, U.S. Patent Application No. 08/899,905, filed July 24, 1997.	
		David Berd, U.S. Patent Application No. 08/942,794, filed October 2, 1997.	
		D. Berd et al., U.S. Patent Application No. 09/447,897, filed November 23, 1999.	
		Sato et al., Cancer Invest., 1997;15:98-105.	
		Kim et al., Eur. J. Immunol., 1992;22:775-782.	
		Sherman et al., J. Immunol., 1978;121:1432-1436.	
		Grabbe et al., Immunol.Today, 1995;16:117-121.	
		Siena et al., Exp. Hematol., 1995;23:1463-1471.	

	 ·	
Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	complete if Known			
Substitute to Form 1449/PTO	Application Number	09/776,250		
INFORMATION DISCLOSURE	Filing Date	February 1, 2001		
STATEMENT BY APPLICANT	First Named Inventor	David Berd		
(Use as many sheets as necessary)	Art Unit	1643		
(Use as many sneets as necessary)	Examiner Name	Karen A. Canella, Ph.D.		
Sheet 3 of 5	Attorney Docket Number	061266-5004-00		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Sahasrabudhe et al., J. Immunol., 1993;151:6302-6310.	
		Shamamian et al., Cancer Immunol. Immunother., 1994;39:73-83.	
		Cox et al., Science, 1994:264:716-719.	
		Peoples et al., J. Immunol., 1993;151:5481-5491.	
	- 1.	Jerome et al., Cancer Res., 1991;51:2908-2916.	
		Morioka et al., J. Immunol., 1994;153:5650-5658.	
		Burrows et al., J. Neurosci. Res. 1997;49:107-116.	
<del></del>		Gavin et al., Eur. J. Immunol., 1994;24:2124-2133.	
		Edman et al., Eur. J. Bio-chem., 1967;1:80-91.	

Examiner		Date	
Signature		Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Complete if Known

Application Number 09/776,250

Filing Date February 1, 2001

First Named Inventor David Berd

Art Unit 1643

Examiner Name Karen A. Canella, Ph.D.

(Use as many sheets as necessary)

tute for form 1449/PTO

Sheet 4 of 5 Attorney Docket Number 061266-5004-00

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Kempkes et al., J. Immunol., 1991;147:2467-2473.	
		Jang et al., Eur. J. Immunol., 1991;21:1303-1310.	
		Pistoor et al., J. Invest. Dermatol., 1995;105:92-95.	
		Nalefski and Rao, J. Immunol., 1993;150:3806-3816.	
		Carlsson, et al., Biochem J., 1978;173:723-737.	
		Miller et al., J. Immunol., 1976;117:191-196.	
		Brown, "Albumin structure, function and uses", Rosenoer, V.M. et al. (eds.), Pergamon Press:Oxford, pp. 27-51, 1977.	
		Weitkamp, L.R., et al., Ann. Hum. Genet., 1973;37:219-226.	
		Hood et al., "Tolerance and the Regulation of Immunity", Second Edition, 1984, Benjamin-Cummings: Menlo Park, CA, pp. 366-401.	
		McCune et al., Cancer, 1979;43:1619-1623.	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. tute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APR 1.8 2007

Sheet

(Use as many sheets as necessary)

5 of

Complete if Known			
Application Number	09/776,250 February 1, 2001		
Filing Date			
First Named Inventor	David Berd		
Art Unit	1643		
Examiner Name	Karen A. Canella, Ph.D.		
Attorney Docket Number	061266-5004-00		

		NON PATENT LITERATURE DOCUMENTS	·
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Pulaski et al., Cancer Res., 1998;58:1486-1493.	
		Berd et al., J. Clin. Oncol., 1997;15:2359-2370.	
		Rennke et al., Kidney International, 1994;45:1044-1056.	
		Heppner et al., Cancer Res. 1978;38:3758-3763.	
		Miller et al., Cancer Res., 1981;41:3863-3867.	
		Miller, Invasion Metastasis, 1981;1:220-226.	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.